Antonio Carlos Wolff

US Patent:

20140221242, Aug 7, 2014

Filed:

Jul 16, 2012

Appl. No.:

14/232981

Inventors:

Saraswati V. Sukumar - Columbia MD, US
Christopher Benedict Umbricht - Towson MD, US
Antonio C. Wolff - Baltimore MD, US
Mary Jo Steele Fackler - Hunt Valley MD, US
Zhe Zhang - Columbia MD, US
Leslie M. Cope - Baltimore MD, US
Kala Visvanathan - Baltimore MD, US
Peng Huang - Owings Mills MD, US

Assignee:

THE JOHN HOPKINS UNIVERSITY - Baltimore MD

International Classification:

C12Q 1/68

US Classification:

506 9, 506 16

Abstract:

To better understand the biology of hormone receptor-positive and negative breast cancer and to identify methylated gene markers of disease progression, a genome-wide methylation array analysis was performed on 103 primary invasive breast cancers and 21 normal breast samples using the Illumina Infinium HumanMethylation27 array that queried 27,578 CpG loci. Forty CpG loci showed differential methylation specific to either ER-positive or ER-negative tumors. Each of the 40 ER-subtype-specific loci was validated in silico using an independent, publicly available methylome dataset from The Cancer Genome Atlas (TCGA). In addition, 100 methylated CpG loci were identified that were significantly associated with disease progression. Arrays containing the ER-subtype-specific loci and their use in methods of diagnosis and treatment of breast cancer are provided.